Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.59 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30879129 | 0.87 | MEN1 (0.56) | MAPTSIRT6ALDH1A1LMNAMEN1 | |
| SCHEMBL23104698 | 0.83 | MAPT (0.56) | MAPTSIRT6ALDH1A1LMNAMEN1 | |
| SCHEMBL10035934 | 0.82 | POLB (0.59) | MAPTSIRT6ALDH1A1LMNAMEN1 | |
| SCHEMBL25447159 | 0.82 | MAPT (0.59) | MAPTSIRT6ALDH1A1LMNAMEN1 | |
| SCHEMBL21526566 | 0.81 | MAPT (0.58) | MAPTSIRT6ALDH1A1LMNAMEN1 | |
| SCHEMBL6714560 | 0.80 | MEN1 (0.73) | MAPTSIRT6ALDH1A1LMNAMEN1 | |
| SCHEMBL27789 | 0.80 | MAPT (0.64) | MAPTSIRT6ALDH1A1LMNAMEN1 | |
| SCHEMBL25175239 | 0.79 | MAPT (0.55) | MAPTSIRT6ALDH1A1LMNAMEN1 | |
| SCHEMBL15244285 | 0.79 | MAPT (0.55) | MAPTSIRT6ALDH1A1LMNAMEN1 | |
| SCHEMBL25176060 | 0.79 | MAPT (0.60) | MAPTSIRT6ALDH1A1LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210070748-A1 | INHIBITORS OF BRUTONS TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2021-03-11 | — | — | US | disclosed |
| WO-2016196776-A2 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC. (US) | 2016-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210070748-A1 | INHIBITORS OF BRUTONS TYROSINE KINASE | BTK, LYN, LCK | MAPT 4203/4885SIRT6 2953/4885ALDH1A1 4726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.